LAVA Therapeutics (LVTX) Institutional Ownership → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Free LVTX Stock Alerts $2.71 -0.12 (-4.24%) (As of 04/19/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for LAVA Therapeutics (NASDAQ:LVTX)Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$1.11MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$824.45K Get LVTX Insider Trade Alerts Want to know when executives and insiders are buying or selling LAVA Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LVTX Institutional Buying and Selling by Quarter Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story LAVA Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/10/2024 Pathway Financial Advisors LLC14,000$47K0.0%N/A0.000% 2/15/2024Novo Holdings A S1,878,194$2.97M0.2%-21.7%7.409% 2/15/2024Citadel Advisors LLC21,552$34K0.0%N/A0.085% 8/11/2023PNC Financial Services Group Inc.65,000$132K0.0%+30.0%0.000% 5/12/2023Bruce & Co. Inc.671,874$1.12M0.3%+571.9%2.650% 5/12/2023Bank of America Corp DE32,240$54K0.0%+20,566.7%0.127% Get the Latest News and Ratings for LVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2023Bruce & Co. Inc.100,000$350K0.1%N/A0.394% 2/15/2023Silverarc Capital Management LLC437,762$1.53M0.4%-28.3%1.727% 2/13/2023Renaissance Technologies LLC18,800$66K0.0%N/A0.074% 2/10/2023PNC Financial Services Group Inc.50,000$175K0.0%N/A0.197% 2/1/2023Bank of Montreal Can89,600$530K0.0%N/A0.353% 11/14/2022UBS Oconnor LLC75,000$343K0.0%N/A0.296% 10/28/2022Silverarc Capital Management LLC610,809$2.79M0.9%N/A2.409% 8/16/2022DAFNA Capital Management LLC128,335$379K0.1%-7.9%0.506% 8/15/2022Nantahala Capital Management LLC322,980$953K0.0%-3.3%1.274% 8/15/2022Point72 Asset Management L.P.111,993$330K0.0%-4.3%0.442% 8/15/2022Millennium Management LLC96,405$276K0.0%-36.0%0.380% 5/13/2022Nantahala Capital Management LLC334,164$1.47M0.1%-7.4%1.318% 2/14/2022Point72 Asset Management L.P.119,152$655K0.0%-3.8%0.470% 11/15/2021Point72 Asset Management L.P.123,911$734K0.0%N/A0.489% 11/15/2021AXA S.A.229,121$1.36M0.0%+3.8%0.904% 11/12/2021Falcon Edge Capital LP140,229$830K0.1%-3.2%0.553% 8/17/2021Woodline Partners LP86,904$946K0.0%-23.3%0.343% 8/17/2021Millennium Management LLC138,831$1.51M0.0%-38.6%0.548% 8/16/2021Redmile Group LLC2,816,196$30.64M0.5%-0.3%11.108% 8/13/2021Geode Capital Management LLC12,997$141K0.0%N/A0.051% 8/11/2021Bank of New York Mellon Corp25,288$275K0.0%-26.3%0.100% 8/10/2021Nicholas Investment Partners LP781,867$8.51M0.5%-4.0%3.084% 8/2/2021New York State Common Retirement Fund19,136$208K0.0%-26.3%0.075% 5/27/2021Davidson Kempner Capital Management LP2,000$30K0.0%N/A0.008% 5/18/2021Millennium Management LLC226,205$3.44M0.0%N/A0.892% 5/18/2021Point72 Asset Management L.P.5,561$84K0.0%N/A0.022% 5/18/2021Tudor Investment Corp Et Al19,614$298K0.0%N/A0.077% 5/18/2021Redmile Group LLC2,824,409$42.90M0.6%N/A11.141% 5/18/2021Davidson Kempner Capital Management LP2,000$30K0.0%N/A0.008% 5/18/2021Citadel Advisors LLC60,442$918K0.0%N/A0.238% 5/18/2021Falcon Edge Capital LP150,454$2.29M0.1%N/A0.593% 5/17/2021Point72 Hong Kong Ltd9,355$142K0.0%N/A0.037% 5/17/2021Woodline Partners LP113,242$1.72M0.0%N/A0.447% 5/17/2021Caas Capital Management LP30,000$456K0.0%N/A0.118% Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>>5/17/2021Pinz Capital Management LP25,900$393K0.1%N/A0.102% 5/17/2021Sphera Funds Management LTD.213,894$3.25M0.2%N/A0.844% 5/17/2021Novo Holdings A S3,327,312$50.54M2.1%N/A13.124% 5/14/2021Nantahala Capital Management LLC381,227$5.79M0.2%N/A1.504% 5/14/2021Nicholas Investment Partners LP814,840$12.38M0.9%N/A3.214% 5/14/2021Monashee Investment Management LLC265,000$3.02M0.5%N/A1.045% 5/13/2021Bank of New York Mellon Corp34,319$521K0.0%N/A0.135% 5/12/2021Pura Vida Investments LLC54,000$820K0.0%N/A0.213% (Data available from 1/1/2016 forward) LVTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LVTX shares? During the previous two years, 14 institutional investors and hedge funds held shares of LAVA Therapeutics. The most heavily invested institutionals were Novo Holdings A S ($2.97M), Silverarc Capital Management LLC ($1.53M), Bruce & Co. Inc. ($1.12M), Nantahala Capital Management LLC ($953K), Bank of Montreal Can ($530K), DAFNA Capital Management LLC ($379K), and UBS Oconnor LLC ($343K).Learn more on LVTX's institutional investors. Which institutional investors have been buying LAVA Therapeutics stock? Of the 9 institutional investors that purchased LAVA Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bruce & Co. Inc. ($671.87K), Silverarc Capital Management LLC ($610.81K), Bank of Montreal Can ($89.60K), UBS Oconnor LLC ($75K), PNC Financial Services Group Inc. ($65K), Bank of America Corp DE ($32.08K), and Citadel Advisors LLC ($21.55K). How much institutional buying is happening at LAVA Therapeutics? Institutional investors have bought a total of 1,598,719 shares in the last 24 months. This purchase volume represents approximately $5.15M in transactions. Which LAVA Therapeutics major shareholders have been selling company stock? The following institutional investors have sold LAVA Therapeutics stock in the last 24 months: Novo Holdings A S ($521.81K), Silverarc Capital Management LLC ($173.05K), Millennium Management LLC ($54.23K), Nantahala Capital Management LLC ($37.83K), DAFNA Capital Management LLC ($11.00K), and Point72 Asset Management L.P. ($4.99K). How much institutional selling is happening at LAVA Therapeutics? Institutional investors have sold a total of 802,891 shares in the last 24 months. This volume of shares sold represents approximately $1.79M in transactions. Related Companies: Context Therapeutics Major Shareholders Grifols Major Shareholders Mainz Biomed Major Shareholders NLS Pharmaceutics Major Shareholders Pharvaris Major Shareholders Procaps Group Major Shareholders Tiziana Life Sciences Major Shareholders Alpha Tau Medical Major Shareholders Alvotech Major Shareholders Alvotech Major Shareholders This page (NASDAQ:LVTX) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsSHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving TrendsUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.